About
Technology
Issues
FAQ
Links
Official Page
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.